Free Trial

Dominari (DOMH) Competitors

Dominari logo
$5.39 -0.22 (-3.92%)
As of 04:00 PM Eastern

DOMH vs. VNDA, VSTM, CDXS, AGEN, IRWD, SGMO, ACHV, FBIO, SABS, and CRIS

Should you be buying Dominari stock or one of its competitors? The main competitors of Dominari include Vanda Pharmaceuticals (VNDA), Verastem (VSTM), Codexis (CDXS), Agenus (AGEN), Ironwood Pharmaceuticals (IRWD), Sangamo Therapeutics (SGMO), Achieve Life Sciences (ACHV), Fortress Biotech (FBIO), SAB Biotherapeutics (SABS), and Curis (CRIS). These companies are all part of the "biotechnology" industry.

Dominari vs. Its Competitors

Vanda Pharmaceuticals (NASDAQ:VNDA) and Dominari (NASDAQ:DOMH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Dominari had 1 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 1 mentions for Dominari and 0 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 0.94 beat Dominari's score of 0.93 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Vanda Pharmaceuticals Positive
Dominari Positive

Vanda Pharmaceuticals currently has a consensus price target of $16.50, indicating a potential upside of 245.19%. Given Vanda Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Vanda Pharmaceuticals is more favorable than Dominari.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vanda Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.50
Dominari
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Dominari has lower revenue, but higher earnings than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Dominari, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vanda Pharmaceuticals$198.77M1.42-$18.90M-$0.75-6.37
Dominari$18.15M4.35-$14.70M-$4.50-1.20

Vanda Pharmaceuticals has a net margin of -21.98% compared to Dominari's net margin of -167.73%. Vanda Pharmaceuticals' return on equity of -8.30% beat Dominari's return on equity.

Company Net Margins Return on Equity Return on Assets
Vanda Pharmaceuticals-21.98% -8.30% -6.85%
Dominari -167.73%-91.67%-77.80%

Vanda Pharmaceuticals has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Comparatively, Dominari has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500.

88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.5% of Dominari shares are owned by institutional investors. 10.0% of Vanda Pharmaceuticals shares are owned by company insiders. Comparatively, 33.0% of Dominari shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Vanda Pharmaceuticals beats Dominari on 12 of the 17 factors compared between the two stocks.

Get Dominari News Delivered to You Automatically

Sign up to receive the latest news and ratings for DOMH and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DOMH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DOMH vs. The Competition

MetricDominariMED IndustryMedical SectorNASDAQ Exchange
Market Cap$82.22M$2.73B$5.54B$9.41B
Dividend YieldN/A1.79%3.75%4.04%
P/E Ratio-1.208.9421.0119.84
Price / Sales4.35697.47433.8199.59
Price / CashN/A161.2636.1657.94
Price / Book0.945.008.125.65
Net Income-$14.70M$30.99M$3.25B$258.00M
7 Day Performance8.02%1.69%0.97%2.09%
1 Month Performance-13.76%9.20%7.36%11.13%
1 Year Performance191.35%-1.25%31.31%18.40%

Dominari Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DOMH
Dominari
0.7992 of 5 stars
$5.39
-3.9%
N/A+201.6%$82.22M$18.15M-1.204
VNDA
Vanda Pharmaceuticals
4.7135 of 5 stars
$4.89
flat
$16.50
+237.4%
-21.9%$288.19M$201.35M-6.52290
VSTM
Verastem
3.1277 of 5 stars
$4.61
-1.7%
$13.38
+190.1%
+49.4%$254.47M$10M-1.4550
CDXS
Codexis
3.4814 of 5 stars
$2.66
+3.1%
$11.00
+313.5%
-16.3%$220.88M$59.35M-2.69250Positive News
AGEN
Agenus
4.2638 of 5 stars
$4.92
-5.0%
$14.00
+184.6%
-62.1%$135.71M$99.52M-0.57440
IRWD
Ironwood Pharmaceuticals
4.3633 of 5 stars
$0.76
+6.3%
$4.78
+531.0%
-88.4%$123.63M$351.41M-3.82220Positive News
SGMO
Sangamo Therapeutics
2.7547 of 5 stars
$0.51
-0.7%
$4.50
+785.8%
+10.8%$118.68M$57.80M-1.31480Positive News
Gap Up
ACHV
Achieve Life Sciences
3.1513 of 5 stars
$2.15
+3.6%
$14.33
+568.2%
-43.4%$74.79MN/A-1.6120
FBIO
Fortress Biotech
2.5744 of 5 stars
$1.97
+3.1%
$21.00
+966.0%
-4.5%$58.40M$57.67M-0.89170Positive News
SABS
SAB Biotherapeutics
3.6398 of 5 stars
$2.04
+4.1%
$13.25
+549.5%
-2.7%$18.95M$1.32M-0.55140News Coverage
CRIS
Curis
2.6204 of 5 stars
$1.80
+3.7%
$17.00
+842.4%
-72.2%$18.83M$11.20M-0.2960

Related Companies and Tools


This page (NASDAQ:DOMH) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners